CombiGene AB (publ) (COMBI.ST)
SEK 2.38
(-2.46%)
SEK 2.38
(-2.46%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -36.3 Million SEK | -458.26% |
| 2022 | -6.94 Million SEK | -133.14% |
| 2021 | 20.96 Million SEK | 174.45% |
| 2020 | -28.15 Million SEK | -59.17% |
| 2019 | -17.69 Million SEK | -34.22% |
| 2018 | -13.18 Million SEK | -47.14% |
| 2017 | -8.95 Million SEK | -3.36% |
| 2016 | -8.66 Million SEK | -38.57% |
| 2015 | -6.25 Million SEK | -550.56% |
| 2014 | -961.36 Thousand SEK | -3397.78% |
| 2013 | -27.48 Thousand SEK | -181.64% |
| 2012 | -9759.00 SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -7.98 Million SEK | 47.6% |
| 2024 Q1 | -15.23 Million SEK | -71.33% |
| 2023 Q1 | -14.61 Million SEK | -22.4% |
| 2023 Q4 | -8.89 Million SEK | -5.87% |
| 2023 Q3 | -8.4 Million SEK | -33.63% |
| 2023 FY | -38.78 Million SEK | -458.26% |
| 2023 Q2 | -6.28 Million SEK | 57.0% |
| 2022 Q3 | 3.95 Million SEK | -12.49% |
| 2022 FY | -6.94 Million SEK | -133.14% |
| 2022 Q1 | -2.68 Million SEK | -104.67% |
| 2022 Q2 | 4.51 Million SEK | 268.26% |
| 2022 Q4 | -11.94 Million SEK | -402.18% |
| 2021 Q2 | -15.4 Million SEK | -41.88% |
| 2021 Q1 | -10.85 Million SEK | 10.76% |
| 2021 Q3 | -10.22 Million SEK | 33.62% |
| 2021 Q4 | 57.44 Million SEK | 661.84% |
| 2021 FY | 20.96 Million SEK | 174.45% |
| 2020 Q3 | -6.41 Million SEK | -115.34% |
| 2020 Q2 | -2.98 Million SEK | 58.54% |
| 2020 Q1 | -7.18 Million SEK | 24.9% |
| 2020 FY | -28.15 Million SEK | -59.17% |
| 2020 Q4 | -12.16 Million SEK | -89.57% |
| 2019 Q3 | -3.57 Million SEK | -27.19% |
| 2019 Q4 | -9.57 Million SEK | -167.44% |
| 2019 FY | -17.69 Million SEK | -34.22% |
| 2019 Q1 | -2.47 Million SEK | 20.0% |
| 2019 Q2 | -2.81 Million SEK | -13.88% |
| 2018 Q1 | -1.99 Million SEK | 39.3% |
| 2018 FY | -13.18 Million SEK | -47.14% |
| 2018 Q4 | -3.08 Million SEK | 47.94% |
| 2018 Q3 | -5.93 Million SEK | -174.8% |
| 2018 Q2 | -2.15 Million SEK | -8.0% |
| 2017 Q1 | 249 Thousand SEK | 110.31% |
| 2017 FY | -8.95 Million SEK | -3.36% |
| 2017 Q4 | -3.29 Million SEK | -16.98% |
| 2017 Q3 | -2.81 Million SEK | 9.22% |
| 2017 Q2 | -3.1 Million SEK | -1345.38% |
| 2016 Q1 | -1.39 Million SEK | 45.94% |
| 2016 FY | -8.66 Million SEK | -38.57% |
| 2016 Q4 | -2.41 Million SEK | 3.77% |
| 2016 Q3 | -2.5 Million SEK | -6.95% |
| 2016 Q2 | -2.34 Million SEK | -67.93% |
| 2015 Q3 | -1.11 Million SEK | 35.31% |
| 2015 Q1 | -1.05 Million SEK | -17.42% |
| 2015 FY | -6.25 Million SEK | -550.56% |
| 2015 Q4 | -2.58 Million SEK | -132.41% |
| 2015 Q2 | -1.71 Million SEK | -62.78% |
| 2014 Q3 | -46 Thousand SEK | 0.0% |
| 2014 Q4 | -899.36 Thousand SEK | -1855.14% |
| 2014 Q2 | - SEK | 100.0% |
| 2014 Q1 | -16 Thousand SEK | 0.0% |
| 2014 FY | -961.36 Thousand SEK | -3397.78% |
| 2013 FY | -27.48 Thousand SEK | -181.64% |
| 2012 FY | -9759.00 SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 90.555% |
| AcouSort AB (publ) | -17.48 Million SEK | -107.612% |
| Active Biotech AB (publ) | -46.48 Million SEK | 21.898% |
| Alzinova AB (publ) | -16.52 Million SEK | -119.738% |
| Amniotics AB (publ) | -29.07 Million SEK | -24.876% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -147.986% |
| BioArctic AB (publ) | 252.64 Million SEK | 114.37% |
| Camurus AB (publ) | 532.35 Million SEK | 106.82% |
| Cantargia AB (publ) | -290.01 Million SEK | 87.482% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -80.273% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -112.357% |
| Genovis AB (publ.) | 54.22 Million SEK | 166.954% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 68.45% |
| Mendus AB (publ) | -100.65 Million SEK | 63.929% |
| Kancera AB (publ) | -65.04 Million SEK | 44.182% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -935.811% |
| LIDDS AB (publ) | -40.67 Million SEK | 10.741% |
| Lipum AB (publ) | -37.25 Million SEK | 2.547% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -193.47% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 301.595% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -121.359% |
| NextCell Pharma AB | -43.17 Million SEK | 15.906% |
| OncoZenge AB (publ) | -15.9 Million SEK | -128.306% |
| Saniona AB (publ) | -81.06 Million SEK | 55.215% |
| Simris Alg AB (publ) | -36.63 Million SEK | 0.9% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 88.708% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 88.305% |
| Xintela AB (publ) | -57.23 Million SEK | 36.572% |
| Ziccum AB (publ) | -21.56 Million SEK | -68.391% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 12.902% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 79.916% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 75.23% |
| Intervacc AB (publ) | -93.57 Million SEK | 61.204% |
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 85.419% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -4196.469% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -134.046% |
| Corline Biomedical AB | -1.78 Million SEK | -1930.49% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 79.916% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 34.487% |
| Aptahem AB (publ) | -10.1 Million SEK | -259.288% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 73.031% |
| Fluicell AB (publ) | -26.87 Million SEK | -35.069% |
| Biovica International AB (publ) | -126.07 Million SEK | 71.203% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 14.586% |
| Abliva AB (publ) | -96.54 Million SEK | 62.397% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 88.822% |
| 2cureX AB (publ) | -36.36 Million SEK | 0.159% |
| I-Tech AB | 24.43 Million SEK | 248.579% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 95.396% |
| Cyxone AB (publ) | -21.66 Million SEK | -67.606% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 65.739% |
| Biosergen AB | -27.26 Million SEK | -33.157% |
| Nanologica AB (publ) | -69.96 Million SEK | 48.108% |
| SynAct Pharma AB | -224.49 Million SEK | 83.828% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 17.817% |
| BioInvent International AB (publ) | -369.94 Million SEK | 90.186% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -51.56% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 85.675% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -467.867% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 67.267% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -213.896% |